Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Chengdu Ruimu Biopharmaceuticals Co. Ltd. has 3 pending office actions in the Biotechnology & Pharmaceuticals sector. These actions are distributed across 3 distinct examiners and 3 distinct art units. VIGIL, TORIANA NICHOLE is the busiest examiner, managing 1 pending action.
The spread of actions across different art units suggests a broad range of pharmaceutical technologies being pursued. Because each of the 3 pending office actions is handled by a different examiner, the company must manage multiple points of contact within the patent office simultaneously.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIGIL, TORIANA NICHOLE | 1 | 53.1% | +24.1% |
| TRAN, SUSAN T | 1 | 62.8% | +35.1% |
| RAO, SAVITHA M | 1 | 60.7% | +30.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262637 | OPHTHALMIC PREPARATION FOR TREATING MACULAR EDEMA, OPTIC NEURITIS AND NON-INFECTIOUS ENDOPHTHALMITIS THROUGH EYE DROP ADMINISTRATION | TRAN, SUSAN T | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717660 | OPHTHALMIC PREPARATION OF TYROSINE KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | VIGIL, TORIANA NICHOLE | — |
| 18262637 | OPHTHALMIC PREPARATION FOR TREATING MACULAR EDEMA, OPTIC NEURITIS AND NON-INFECTIOUS ENDOPHTHALMITIS THROUGH EYE DROP ADMINISTRATION | TRAN, SUSAN T | — |
| 18262628 | OPHTHALMIC PREPARATION ADMINISTERED BY EYE DROPS AND USED FOR PREVENTING AND TREATING DRY MACULAR DEGENERATION AND RETINAL LIGHT DAMAGE | RAO, SAVITHA M | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1615 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717660 | OPHTHALMIC PREPARATION OF TYROSINE KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | VIGIL, TORIANA NICHOLE | 1612 | §103 | Final Rejection | — | Pending | Jun 07, 2024 |
| 18262637 | OPHTHALMIC PREPARATION FOR TREATING MACULAR EDEMA, OPTIC NEURITIS AND NON-INFECTIOUS ENDOPHTHALMITIS THROUGH EYE DROP ADMINISTRATION | TRAN, SUSAN T | 1615 | §102§103§112Other | Final Rejection | — | Pending | Apr 17, 2024 |
| 18262628 | OPHTHALMIC PREPARATION ADMINISTERED BY EYE DROPS AND USED FOR PREVENTING AND TREATING DRY MACULAR DEGENERATION AND RETINAL LIGHT DAMAGE | RAO, SAVITHA M | 1691 | §103 | Final Rejection | — | Pending | Oct 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial